Pfizer and Renovis have extended the term of their worldwide collaboration to research, develop and commercialize small molecules that target the vanilloid receptor, VR1. This extension provides Renovis with additional research funding through June 30, 2008 and reflects the goal of Pfizer and Renovis to advance multiple, small molecule VR1 antagonists toward clinical development. The VR1 receptor is a member of a related group of ion channel proteins known as the transient receptor potential ...